NEW YORK, June 3, 2022 /PRNewswire/ — The infectious enteritis treatment market will be driven by factors such as the increasing geriatric population in countries such as Japan, Italy, and the US. For instance, as per the United Nations (UN) Department of Economic and Social Affairs, the geriatric population (people aged 65 or over) was 702.9 million in 2019 and 727 million in 2020. Similarly, the geriatric population in India will increase by 41% over the next decade to reach 194 million in 2031. This increase in the percentage of the geriatric population is increasing the demand for the treatment of hospital-acquired infections around the world.
The infectious enteritis treatment market size is expected to grow by USD 403.92 million from 2021 to 2026. Moreover, the growth of the market will accelerate at a CAGR of 5.09% during the forecast period.
Request Latest Sample Report to learn about additional highlights related to market dynamics
Infectious Enteritis Treatment Market 2022-2026: Scope
The infectious enteritis treatment market report covers the following areas:
Subscribe to our “Basic Plan” billed annually at USD 5000. Get lifetime access to our Technavio Insights
Infectious Enteritis Treatment Market 2022-2026: Vendor Analysis
The infectious enteritis treatment market is fragmented, and the vendors are deploying growth strategies such as geographical expansion, product portfolio expansion, and product innovation to compete in the market. The market has intense competition due to the presence of several global, regional, and local vendors. Abbott Laboratories, Almirall SA, Cipla Ltd., Zydus Lifesciences Ltd., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Hetero Healthcare Ltd., Mayne Pharma Group Ltd., Medimetriks Pharmaceuticals Inc., Merck KGaA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Tolmar Pharmaceuticals Inc., and Viatris Inc. are among some of the major market participants.
To learn more about major key vendors and vendor offerings, View an Exclusive Sample Report
Infectious Enteritis Treatment Market 2022-2026: Segmentation
-
Geography
-
Route of administration
Infectious Enteritis Treatment Market 2022-2026: Key Highlights
-
CAGR of the market during the forecast period 2022-2026
-
Detailed information on factors that will assist infectious enteritis treatment market growth during the next five years
-
Estimation of the infectious enteritis treatment market size and its contribution to the parent market
-
Predictions on upcoming trends and changes in consumer behavior
-
The growth of the infectious enteritis treatment market
-
Analysis of the market’s competitive landscape and detailed information on vendors
-
Comprehensive details of factors that will challenge the growth of infectious enteritis treatment market, vendors
Related Reports
Herpes Zoster Therapeutics Market by Product and Geography – Forecast and Analysis 2022-2026
Nicotine Patch Market by Product and Geography – Forecast and Analysis 2022-2026
|
Infectious Enteritis Treatment Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2021 |
|
Forecast period |
2022-2026 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.09% |
|
Market growth 2022-2026 |
USD 403.92 million |
|
Market structure |
Fragmented |
|
YoY growth (%) |
3.52 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 37% |
|
Key consumer countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
|
Companies profiled |
Abbott Laboratories, Almirall SA, Cipla Ltd., Zydus Lifesciences Ltd., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Hetero Healthcare Ltd., Mayne Pharma Group Ltd., Medimetriks Pharmaceuticals Inc., Merck KGaA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Tolmar Pharmaceuticals Inc., and Viatris Inc. |
|
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for the forecast period, |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Contents:
1 Executive Summary
-
1.1 Market overview
2 Market Landscape
-
2.1 Market ecosystem
3 Market Sizing
-
3.1 Market definition
-
3.3 Market size 2021
4 Five Forces Analysis
-
4.1 Five forces summary
-
4.6 Threat of rivalry
-
4.7 Market condition
5 Market Segmentation by Route of Administration
-
5.1 Market segments
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
-
8.1 Market drivers
-
8.2 Market challenges
-
8.4 Market trends
9 Vendor Landscape
-
9.1 Overview
-
9.2 Vendor landscape
-
9.3 Landscape disruption
-
9.4 Industry risks
10 Vendor Analysis
-
10.1 Vendors covered
-
10.3 Abbott Laboratories
-
10.4 Almirall SA
-
10.5 Cipla Ltd.
-
10.7 Galderma SA
-
10.8 GlaxoSmithKline Plc
-
10.11 Pfizer Inc.
-
10.12 Viatris Inc.
11 Appendix
-
11.1 Scope of the report
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/infectious-enteritis-treatment-market-size-to-grow-by-usd-403-92-million–increasing-geriatric-population-to-drive-growth–technavio-301560211.html
SOURCE Technavio
